Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Jun 28, 2014; 20(24): 7819-7829
Published online Jun 28, 2014. doi: 10.3748/wjg.v20.i24.7819
Published online Jun 28, 2014. doi: 10.3748/wjg.v20.i24.7819
Table 2 Summary of the most important randomized clinical trials performed in advanced pancreatic ductal adenocarcinoma
| Experimental arm treatment (number of patients included) | Median OS (mo) (Experimental arm) (95%CI) | Control arm treatment (number of patients included) | Median OS (mo) (Control arm) (95%CI) | Hazard ratio (95%CI) (P value) | Ref. |
| Gemcitabine (63 pts) | 5.6 (data not shown) | 5-FU (63 pts) | 4.4 (data not shown) | Data not shown P = 0.0025 | Burris et al[7], 1997 |
| Gemcitabine and erlotinib (285 pts) | 6.24 (data not shown) | Gemcitabine (284 pts) | 5.91 (data not shown) | 0.82 (0.69-0.99) P = 0.038 | Moore et al[8], 2007 |
| Gemcitabine and capecitabine (267 pts) | 7.1 (6.2-7.8) | Gemcitabine (266 pts) | 6.2 (5.5-7.2) | 0.86 (0.72-1.02) P = 0.08 | Cunningham et al[9] 2009 |
| FOLFIRINOX (combination of 5FU, oxaliplatin and irinotecan) (171 pts) | 11.1 (9.0-13.1) | Gemcitabine (171 pts) | 6.8 (5.5-7.6) | 0.57 (0.45-0.73) P < 0.001 | Conroy et al[10], 2011 |
| Gemcitabine and nab-paclitaxel (431 pts) | 8.5 (7.9-9.5) | Gemcitabine (430 pts) | 6.7 (6.0-7.2) | 0.72 (0.62-0.83) P < 0.001 | Von Hoff et al[11], 2013 |
- Citation: Lamarca A, Feliu J. Pancreatic biomarkers: Could they be the answer? World J Gastroenterol 2014; 20(24): 7819-7829
- URL: https://www.wjgnet.com/1007-9327/full/v20/i24/7819.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i24.7819